Australia And New Zealand Radiotherapy Market
Australia and New Zealand Radiotherapy Market Size And Forecast
According to Verified Market Research, the Australia Radiotherapy Market was valued at USD 547.3 Million in 2018 and is projected to reach USD 950.8 Million by 2026, growing at a CAGR of 7.34% from 2019 to 2026. However, the New Zealand Radiotherapy Market was valued at USD 73.2 Million in 2018 and is projected to reach USD 129.0 Million by 2026, growing at a CAGR of 7.48% from 2019 to 2026.
Australia and New Zealand Radiotherapy Market Outlook
A few of the major factors driving the growth of the Radiotherapy market in Australia and New Zealand are the growing number of cancer patients, increasing adoption of radiotherapy devices and procedures, increasing the geriatric population and technological advancements in radiotherapy devices. However, the lack of skilled professionals for radiotherapy may hinder market growth.
Australia and New Zealand Radiotherapy Market, Segment Analysis
Australia and New Zealand Radiotherapy Market are segmented on the basis of End-User, Component, Type, and Country.
Australia and New Zealand Radiotherapy Market, Competitive Landscape
The Australia & New Zealand Radiotherapy Market is highly fragmented with the presence of a large number of players. Some of the major companies Genesis, NL-TEC Pty Ltd, Alphatech Systems Limited, Varian, Elekta, Sirtex, Noxopharm, Philips, Telix Pharmaceutical and Theranostics Australia.
Varian is one of the top five players for the Australia and New Zealand Radiotherapy market.
Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.